PFG Investments LLC Purchases New Position in OPKO Health, Inc. (NASDAQ:OPK)

PFG Investments LLC purchased a new stake in OPKO Health, Inc. (NASDAQ:OPK - Free Report) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 937,265 shares of the biotechnology company's stock, valued at approximately $1,125,000. PFG Investments LLC owned approximately 0.13% of OPKO Health as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of OPKO Health by 11.4% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 776,020 shares of the biotechnology company's stock valued at $931,000 after acquiring an additional 79,525 shares during the period. Moseley Investment Management Inc. acquired a new stake in shares of OPKO Health in the first quarter valued at approximately $41,000. Tower Research Capital LLC TRC boosted its holdings in shares of OPKO Health by 68.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 47,320 shares of the biotechnology company's stock valued at $71,000 after acquiring an additional 19,219 shares during the period. IPG Investment Advisors LLC acquired a new stake in shares of OPKO Health in the fourth quarter valued at approximately $30,000. Finally, BNP Paribas Financial Markets boosted its holdings in shares of OPKO Health by 349.8% in the fourth quarter. BNP Paribas Financial Markets now owns 271,872 shares of the biotechnology company's stock valued at $411,000 after acquiring an additional 211,429 shares during the period. 64.63% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently weighed in on OPK. Piper Sandler reissued an "overweight" rating and issued a $5.00 price objective on shares of OPKO Health in a report on Monday, April 1st. Barrington Research reaffirmed an "outperform" rating and set a $1.50 price target on shares of OPKO Health in a report on Monday, April 1st. HC Wainwright reaffirmed a "buy" rating and set a $3.00 price target on shares of OPKO Health in a report on Wednesday, April 3rd. Finally, StockNews.com downgraded OPKO Health from a "hold" rating to a "sell" rating in a report on Friday, March 1st.

Insider Activity at OPKO Health

In related news, CEO Phillip Md Et Al Frost acquired 1,500,000 shares of the firm's stock in a transaction that occurred on Wednesday, February 7th. The shares were acquired at an average price of $0.98 per share, with a total value of $1,470,000.00. Following the completion of the purchase, the chief executive officer now directly owns 207,368,225 shares in the company, valued at $203,220,860.50. The purchase was disclosed in a document filed with the SEC, which is available through this link. In other OPKO Health news, Director Richard M. Krasno purchased 30,000 shares of the firm's stock in a transaction on Monday, January 29th. The shares were purchased at an average cost of $0.99 per share, with a total value of $29,700.00. Following the purchase, the director now owns 103,333 shares in the company, valued at $102,299.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Phillip Md Et Al Frost purchased 1,500,000 shares of the firm's stock in a transaction on Wednesday, February 7th. The stock was acquired at an average cost of $0.98 per share, for a total transaction of $1,470,000.00. Following the completion of the purchase, the chief executive officer now owns 207,368,225 shares in the company, valued at approximately $203,220,860.50. The disclosure for this purchase can be found here. Insiders have purchased a total of 4,630,000 shares of company stock valued at $4,422,700 over the last quarter. Insiders own 47.26% of the company's stock.

OPKO Health Price Performance

Shares of OPK stock traded up $0.04 during mid-day trading on Friday, reaching $1.26. The stock had a trading volume of 1,947,676 shares, compared to its average volume of 6,337,833. OPKO Health, Inc. has a 12-month low of $0.85 and a 12-month high of $2.24. The company has a market cap of $878.21 million, a P/E ratio of -5.04 and a beta of 1.82. The business has a 50-day simple moving average of $1.10 and a 200 day simple moving average of $1.23. The company has a current ratio of 1.55, a quick ratio of 1.22 and a debt-to-equity ratio of 0.15.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($0.09) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.09). OPKO Health had a negative return on equity of 12.69% and a negative net margin of 21.76%. The business had revenue of $181.90 million during the quarter, compared to analysts' expectations of $177.53 million. During the same quarter last year, the business posted ($0.11) earnings per share. The business's revenue for the quarter was down 1.9% on a year-over-year basis. On average, sell-side analysts anticipate that OPKO Health, Inc. will post -0.33 earnings per share for the current year.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.

Want to see what other hedge funds are holding OPK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OPKO Health, Inc. (NASDAQ:OPK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.